New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 21, 2014
10:00 EDTWBC, RICE, MMYT, ENBL, CNP, VRX, OGE, LIQD, CVA, BAC, TSRE, DNOW, JPM, C, ACAS, ALLYOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Ally Financial (ALLY) initiated with a Market Perform at Bernstein... American Capital (ACAS) initiated with a Buy at Sterne Agee... Bank of America (BAC) initiated with a Buy at MKM Partners... CenterPoint Energy (CNP) reinstated with an Equalweight at Barclays... Citigroup (C) initiated with a Buy at MKM Partners... Covanta (CVA) initiated with a Buy at BB&T... Enable Midstream (ENBL) initiated with a Buy at UBS... JPMorgan (JPM) initiated with a Buy at MKM Partners... Liquid Holdings (LIQD) initiated with an Outperform at JMP Securities... MakeMyTrip (MMYT) initiated with a Buy at Citigroup... NOW Inc. (DNOW) initiated with an Overweight at JPMorgan... OGE Energy (OGE) initiated with an Overweight at Barclays... Rice Energy (RICE) initiated with a Buy at Mizuho... Trade Street Residential (TSRE) initiated with a Buy at Compass Point... Valeant (VRX) initiated with an Outperformer at CIBC... WABCO (WBC) initiated with a Buy at Longbow.
News For ALLY;ACAS;BAC;CNP;C;CVA;ENBL;JPM;LIQD;MMYT;DNOW;OGE;RICE;TSRE;VRX;WBC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
June 17, 2015
11:41 EDTVRXSynergy an 'attractive takeout target' after data, says Cantor
Subscribe for More Information
11:16 EDTBAC, JPM, COCC restricts some banks from certain mortgage related business activity
Subscribe for More Information
10:44 EDTVRXSynergy a potential takeover target after constipation drug data
The shares of Synergy Pharmaceuticals (SGYP) are rallying after the company announced that its chronic constipation treatment had met its primary endpoint in a Phase 3 clinical trial. Research firm Canaccord has previously identified Synergy as a potential takeover target and a Bloomberg report said the company had hired advisers to explor a potential sale. WHAT'S NEW: Synergy reported this morning that the 3 mg and 6 mg versions of its anti-constipation drug, plecanatide, had met their primary endpoint in a Phase III trial. Specifically, a statistically significant percentage of patients taking both versions of the drugs responded favorably, based on criteria that the FDA uses to determine approval of chronic constipation treatments, the company stated. Plecanatide was safe and well tolerated at both dose, and the results were positive, the company reported. "These results strengthen our belief that plecanatide has the potential to not only effectively treat constipation but with a durability and tolerability profile that is ideal for chronic use," said Synergy CEO Gary Jacob. "We look forward to the results of our second pivotal trial in the coming weeks," he added. WHAT'S NOTABLE: In a note to investors on May 22, Canaccord analyst Corey Davis initiated coverage of Synergy with a Buy rating. There is "a high likelihood" that data from the company's four Phase III trials due to be conducted over the next year will be positive and the company would be an attractive takeover target if its Phase III data is positive, Jacobs wrote. The analyst placed an $11 price target on the shares. Meanwhile, in March, Bloomberg reported that Synergy was talking to advisers about potentially selling the company after its competitor, Salix Pharmaceuticals, had agreed to be acquired by Valeant Pharmaceuticals (VRX). After the company reported the trial results today, its CEO told Bloomberg that "all options are on the table." IRONWOOD: The shares of Ironwood (IRWD), whose Linzess drug also treats chronic constipation, are falling today following Synergy's data readout. Canaccord's Davis had said that the diarrhea rate of patients taking Synergy's plecanatide had to come in at 10% or lower for the drug to achieve "best differentiation" versus Linzess. Patients taking the 3 mg dose of plecanatide had a diarrhea rate of 5.5%, while 5.9% of those taking the 6 mg dose experienced diarrhea, Synergy reported. Linzess is co-marketed by Ironwood and Forest Pharmaceuticals, a unit of Allergan (AGN). PRICE ACTION: In morning trading, Synergy surged 45% to $6.74, while Ironwood slid fractionally to $12.16.
10:00 EDTRICEOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:40 EDTBACActive equity options trading on open
Subscribe for More Information
09:36 EDTBACActive equity options trading on open
Active equity options trading on open: AAPL FB AMD ADBE TWTR BABA QIHU NFLX BAC
08:10 EDTBACFed told BofA it is too reactive to problems raised by regulators, WSJ says
The Federal Reserve told Bank of America earlier this year that it does not think its management is forward-looking enough and is rather too reactive to problems after they are raised by regulators during “stress tests,” the Wall Street Journal reports, citing people familiar with the matter. As a result, in March, the Fed only granted the bank conditional approval to return capital to shareholders, meaning the bank is required to submit a revised stress test plan by September 30, the report says. In response, Bank of America has hired “several” outside consultants to look over the way it runs the tests, the Wall Street Journal reports, citing others close to the situation. Reference Link
06:48 EDTC, JPM, BACMore big banks waiving overdraft fees, WSJ reports
Subscribe for More Information
06:47 EDTRICERice Energy upgraded to Neutral from Sell at Citi
Citi upgraded Rice Energy to Neutral saying the potential for positive operational catalysts in the Utica this year offset capital efficiency concerns. Citi raised its price target for shares to $23 from $18.
05:39 EDTCCiti appointed successor depositary bank for Sodexo ADR program
Citi, acting through Citibank N.A., has been appointed by Sodexo S.A. as successor depositary bank for its Level 1 American Depositary Receipt, or ADR, program, which trades in the U.S. over the counter market under symbol “SDXAY”. The ordinary shares are listed on Euronext Paris and trade under symbol “SW”.
June 16, 2015
18:33 EDTJPMJPMorgan shareholder suit over 'London Whale' dismissed, Reuters reports
Subscribe for More Information
16:01 EDTBACApple Twitter Facebook Bank of America Yahoo Netflix Alibaba WisdomTree Coca-Cola Goldman Sachs Micron General Electric
iPath S&P 500 VIX Short-Term Futures down 33c to 18.68. Option volume leaders: AAPL TWTR FB BAC YHOO NFLX BABA WETF KO GS MU GE.
14:16 EDTCCiti said to have ignored e-mails on lax control at Banamex unit, Bloomberg says
Subscribe for More Information
11:08 EDTVRXValeant in advanced discussions to acquire Amoun, Bloomberg reports
Subscribe for More Information
10:01 EDTALLYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:36 EDTBACActive equity options trading on open
Subscribe for More Information
07:11 EDTC, BAC, JPMSurprise AIG ruling may make future bailouts unlikely, even if needed, NYT says
Subscribe for More Information
06:41 EDTACASAmerican Capital management to meet with Sterne Agee CRT
Subscribe for More Information
06:19 EDTJPMJPMorgan, HSBC could move parts of businesses to Luxembourg, U.K. Times reports
Subscribe for More Information
05:29 EDTALLYAlly Financial upgraded to Buy from Neutral at Goldman
Goldman Sachs upgraded Ally Financial (ALLY) to Buy saying the company's balance sheet restructuring is being undervalued at current share levels. Goldman believes the loss of the General Motors (GM) business is being overly discounted in the valuation and raised its price target for shares to $27 from $24.50. The firm calls Ally one of the most attractive value investments in financials.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use